Overexpression of Bcl-2 and Bcl-xL resulted in the reduction of TRAIL-induced cleavage of caspase-8 and Bid, cleaved blockage of caspase-3, -7, and -9 in non-small-cell lung cancer (NSCLC) and the cleavage of caspase substrates like PARP in glioblastoma, neuroblastoma, and breast cancer cell lines[57]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.